NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aptinyx
With
CogState Ltd.
Worldwide Clinical Trials
The study will be a 16 to 18-week study, including a 2 to 4-week screening period, followed by a 12-week double-blind, randomized, placebo-controlled treatment Period, and a 2-week follow-up period. Subjects eligible for the study will be randomized to receive either NYX-458 or placebo.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed Consent
Diagnosis of Parkinson's disease and mild cognitive impairment or mild dementia OR diagnosis of mild cognitive impairment or mild dementia with Lewy bodies
Presence of subjective cognitive complaints by the patient
Verifiable impairment, as defined a CGI-S (Clinical Global Impression-Severity) score of at least 3 (mildly ill).
Score on the MoCA (Montreal Cognitive Assessment) between 15 and 25, inclusive.
Stable anti-parkinsonian regimen (if applicable)
Has a study partner who can accompany the subject at specified study visits
You may not be if
Clinically meaningful motor complications
Current use of medications with primarily central nervous system activities
Other clinically significant medical histories that may interfere with completing the study.
Clareo Health | NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
